Takes from plenary address at AAIC on ‘Accelerating the Discovery and Development of Medicines for Neurodegeneration‘

Research evidence excerpt

Takes from plenary address at AAIC on ‘Accelerating the Discovery and Development of Medicines for Neurodegeneration‘

Global Research

12 July 2026ab

Denali Therapeutics Inc Equities

United StatesTakes from plenary address at AAIC on

"Accelerating the Discovery and Biotechnology

12-month rating Buy *Development of Medicines for

Neurodegeneration" 12m price target US$25.00

Price (10 Jul 2026) US$25.68

Denali Therapeutics CEO Ryan Watts delivered a plenary address at the RIC: DNLI.O BBG: DNLI US

AAIC conference in London today framing the current moment as one of the Trading data and key metrics

most exciting periods in Alzheimer's research. Historically, progress has been

52-wk range US$27.21-12.75

constrained by three major challenges: understanding disease biology, identifying

Market cap. US$4.43b

meaningful biomarkers and tools to diagnose and select patients, and delivering

Shares o/s 172m (COM)

therapeutics across the BBB which is engineered to only allow select nutrients into the

brain - all questions which the field has now made major steps in solving with now two Free float 67%

approved drugs targeting amyloid beta and emerging validation on tau as a second Avg. daily volume ('000) 1,795

target, progress in biomarker tools including plasma-based approaches which can Avg. daily value (m) US$38.4

screen more patients earlier, and Denali's (and others') own progress in solving the Common s/h equity (12/26E) US$0.62b

question of the BBB. P/BV (12/26E) 7.8x

Net debt to EBITDA (12/26E) 0.9x

Denali is focused on building a platform for delivery of large molecules across EPS (UBS, diluted) (USD)

the BBB and recently got their first FDA approval and the first approval of any 12/26E

drug utilizing BBB-crossing technology in Avlayah for the treatment of Hunter UBS Cons.